EnhancedBio
PrivateLast Round
Series C
Aug 1, 2022
Est. Valuation
$75.8M
Total Funding Raised
$26.25M
Company Overview
EnhancedBio is a biotechnology company that develops innovative anti-cancer therapeutics, including small molecule and siRNA-based therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EnhancedBio Comparables
Compare EnhancedBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pin Therapeutics | 81% | |
| Arvinas Inc | 77% | |
| Ubix Therapeutics | 77% |
EnhancedBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 1, 2022 | ||||
| Series B | Aug 1, 2020 | ||||
| Series A | Feb 22, 2019 |
EnhancedBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Seoul Investment Partners | Series C, Series A |
| Dongyoo Technology Investment | Series A |
| CKD Venture Capital | Series A |
| Hyundai Technology Investment | Series B |
| HB Investment | Series B, Series C |
| MobyDick Ventures | Series C |
| Korea Venture Investment Corporation | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2022
$9.48M round with Mirae Asset Venture Investment.
- Aug 1, 2020
$10.3M round led by HB Investment and Hyundai Technology Investment.
EnhancedBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about EnhancedBio's valuation, stock price, and market status.
Is EnhancedBio a public or private company?
EnhancedBio is a private company.
What is the current stock price of EnhancedBio?
EnhancedBio is a private company with no public stock price. Caplight tracks EnhancedBio's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is EnhancedBio worth (valuation)?
EnhancedBio's valuation is estimated at $75.8M based on funding round data.
Can I buy EnhancedBio stock?
EnhancedBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was EnhancedBio's last funding round?
EnhancedBio's most recent funding round was Series C on August 1, 2022.
Who are the main investors in EnhancedBio?
Key investors in EnhancedBio include Seoul Investment Partners, Dongyoo Technology Investment, CKD Venture Capital, Hyundai Technology Investment, HB Investment.
Will EnhancedBio IPO soon?
No public IPO plans have been announced for EnhancedBio.
How can I track EnhancedBio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor EnhancedBio's secondary market activity and sign up for updates.